scholarly article | Q13442814 |
P50 | author | Henrik Zetterberg | Q6252048 |
Dietmar Fuchs | Q38801487 | ||
Lars Hagberg | Q97650293 | ||
Serena Spudich | Q114411897 | ||
Richard W Price | Q124366832 | ||
P2093 | author name string | Dieter J Meyerhoff | |
Magnus Gisslén | |||
Fang-Yong Li | |||
Kevin Robertson | |||
Elham Rahimy | |||
P2860 | cites work | The effects of psychostimulant drugs on blood brain barrier function and neuroinflammation | Q21129283 |
Acquired immunodeficiency syndrome and the blood-brain barrier | Q24653985 | ||
Cerebrospinal fluid signs of neuronal damage after antiretroviral treatment interruption in HIV-1 infection | Q24810504 | ||
Cerebrospinal fluid neurofilament concentration reflects disease severity in frontotemporal degeneration | Q33610029 | ||
Peripheral neuropathy in primary HIV infection associates with systemic and central nervous system immune activation | Q34099733 | ||
Lower brain glutamate is associated with cognitive deficits in HIV patients: A new mechanism for HIV‐associated neurocognitive disorder | Q34257820 | ||
HIV-associated neurocognitive disorders persist in the era of potent antiretroviral therapy: CHARTER Study | Q34370880 | ||
Cerebral metabolite changes prior to and after antiretroviral therapy in primary HIV infection | Q34466521 | ||
Change in brain magnetic resonance spectroscopy after treatment during acute HIV infection | Q34508049 | ||
Progressive increase in central nervous system immune activation in untreated primary HIV-1 infection | Q34678105 | ||
Cerebrospinal fluid (CSF) neuronal biomarkers across the spectrum of HIV infection: hierarchy of injury and detection | Q34776835 | ||
The role of medical imaging in defining CNS abnormalities associated with HIV-infection and opportunistic infections | Q34787585 | ||
Biomarker evidence of axonal injury in neuroasymptomatic HIV-1 patients | Q35093695 | ||
Central nervous system immune activation characterizes primary human immunodeficiency virus 1 infection even in participants with minimal cerebrospinal fluid viral burden | Q35164448 | ||
Primary HIV type 1 infection | Q35779940 | ||
Neurocognitive decline in HIV patients is associated with ongoing T-cell activation in the cerebrospinal fluid. | Q36072424 | ||
Absence of Cerebrospinal Fluid Signs of Neuronal Injury Before and After Immediate Antiretroviral Therapy in Acute HIV Infection | Q36250205 | ||
Central nervous system viral invasion and inflammation during acute HIV infection | Q36376213 | ||
Persistence of transmitted drug resistance among subjects with primary human immunodeficiency virus infection. | Q36673315 | ||
Cerebrospinal fluid and neuroimaging biomarker abnormalities suggest early neurological injury in a subset of individuals during primary HIV infection | Q36796560 | ||
Diagnosis and management of acute HIV infection | Q36821653 | ||
Cerebral white matter integrity during primary HIV infection | Q37028677 | ||
Matrix metalloproteinase levels in early HIV infection and relation to in vivo brain status | Q37283984 | ||
HIV and neurocognitive dysfunction | Q38122104 | ||
Antiretroviral treatment reduces increased CSF neurofilament protein (NFL) in HIV-1 infection | Q38429930 | ||
CSF neurofilament protein (NFL) -- a marker of active HIV-related neurodegeneration. | Q38433078 | ||
Enhanced normalisation of CD4/CD8 ratio with early antiretroviral therapy in primary HIV infection | Q38860933 | ||
Principles of albumin and IgG analyses in neurological disorders. I. Establishment of reference values | Q40833195 | ||
Calculating correlation coefficients with repeated observations: Part 2--Correlation between subjects | Q41919008 | ||
Calculating correlation coefficients with repeated observations: Part 1--Correlation within subjects | Q41972849 | ||
Increased blood-brain barrier permeability in neuro-asymptomatic HIV-1-infected individuals--correlation with cerebrospinal fluid HIV-1 RNA and neopterin levels | Q43796945 | ||
Human immunodeficiency virus infection of the brain. I. Virus isolation and detection of HIV specific antibodies in the cerebrospinal fluid of patients with varying clinical conditions | Q45833251 | ||
Human immunodeficiency virus type 1 (HIV-1) infection of the central nervous system: an evaluation of cytokines in cerebrospinal fluid | Q45843920 | ||
Early viral brain invasion in iatrogenic human immunodeficiency virus infection | Q45868985 | ||
Longitudinal characterization of depression and mood states beginning in primary HIV infection | Q46834428 | ||
Elevated cerebrospinal fluid levels of monocyte chemotactic protein-1 correlate with HIV-1 encephalitis and local viral replication | Q47672132 | ||
Early penetration of the blood-brain-barrier by HIV. | Q48125248 | ||
Cerebral white matter changes in acquired immunodeficiency syndrome dementia: alterations of the blood-brain barrier | Q48230350 | ||
Protein analyses in cerebrospinal fluid. I. Influence of concentration gradients for proteins on cerebrospinal fluid/serum albumin ratio | Q48353899 | ||
Patterns of cerebral atrophy in HIV-1-infected individuals: results of a quantitative MRI analysis | Q48413062 | ||
Effects of antiretroviral treatment on blood-brain barrier integrity and intrathecal immunoglobulin production in neuroasymptomatic HIV-1-infected patients | Q48899585 | ||
Serum neurofilament light chain in early relapsing remitting MS is increased and correlates with CSF levels and with MRI measures of disease severity. | Q49015259 | ||
HIV-associated neurocognitive disorder - pathogenesis and prospects for treatment. | Q55135038 | ||
Diagnosis of primary HIV-1 infection and duration of follow-up after HIV exposure. Karolinska Institute Primary HIV Infection Study Group | Q64130059 | ||
P433 | issue | 7 | |
P407 | language of work or name | English | Q1860 |
P921 | main subject | blood–brain barrier | Q221694 |
P304 | page(s) | 1132-1140 | |
P577 | publication date | 2017-04-01 | |
P1433 | published in | Journal of Infectious Diseases | Q4051141 |
P1476 | title | Blood-Brain Barrier Disruption Is Initiated During Primary HIV Infection and Not Rapidly Altered by Antiretroviral Therapy | |
P478 | volume | 215 |
Q52699607 | Anti-Human Immunodeficiency Virus Antibodies in the Cerebrospinal Fluid: Evidence of Early Treatment Impact on Central Nervous System Reservoir? |
Q64974601 | Clinical characteristics and cerebro-spinal fluid cytokine changes in patients with acquired immunodeficiency syndrome and central nervous system infection. |
Q54217355 | Distribution of HIV RNA in CSF and Blood is linked to CD4/CD8 Ratio During Acute HIV. |
Q93383858 | Elevated cerebrospinal fluid Galectin-9 is associated with central nervous system immune activation and poor cognitive performance in older HIV-infected individuals |
Q66678727 | Gamma Interferon Alters Junctional Integrity via Rho Kinase, Resulting in Blood-Brain Barrier Leakage in Experimental Viral Encephalitis |
Q51762497 | Global HIV neurology: a comprehensive review. |
Q57807608 | HIV Cerebrospinal Fluid Escape and Neurocognitive Pathology in the Era of Combined Antiretroviral Therapy: What Lies Beneath the Tip of the Iceberg in Sub-Saharan Africa? |
Q46617628 | HIV-1 counteracts an innate restriction by amyloid precursor protein resulting in neurodegeneration |
Q52561597 | Longitudinal Trajectories of Brain Volume and Cortical Thickness in Treated and Untreated Primary HIV Infection. |
Q92360041 | Markers of CNS Injury in Adults Living With HIV With CSF HIV Not Detected vs Detected <20 Copies/mL |
Q99419745 | Methamphetamine and Cannabis: A Tale of Two Drugs and their Effects on HIV, Brain, and Behavior |
Q89483369 | Peripheral and cerebrospinal fluid immune activation and inflammation in chronically HIV-infected patients before and after virally suppressive combination antiretroviral therapy (cART) |
Q64076275 | Targeting the HIV-infected brain to improve ischemic stroke outcome |
Q53075373 | The Aging Brain With HIV Infection: Effects of Alcoholism or Hepatitis C Comorbidity. |
Search more.